XOMA Royalty (XOMA) Stock Price, News & Analysis

Company Overview

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways.

Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.

Key Stats

• Today's Range: $40.17 to $40.17
• 50-Day Range: $39.36 to $45.00
• 52-Week Range: $22.29 to $45.22
• Volume: N/A
• Average Volume: 497,905 shs
• Market Capitalization: $503.77 million
• P/E Ratio: 25.59
• Dividend Yield: N/A
• Price Target: $53.75
• Consensus Rating: Hold

Company Calendar

• Last Earnings: 5/12/2026
• Today: 9/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XOMA
• CIK: 791908
• Web: www.xoma.com
• Phone: (510) 204-7200
• Fax: 510-649-7571
• Employees: 10
• Year Founded: 1981

Price Target and Rating

• Average Price Target for XOMA Royalty: $53.75
• High Price Target: $76.00
• Low Price Target: $39.00
• Potential Upside/Downside: +33.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.57
• Trailing P/E Ratio: 25.59
• Forward P/E Ratio: 44.63
• P/E Growth: N/A
• Net Income: $31.71 million
• Net Margins: 53.46%
• Pretax Margin: 69.85%
• Return on Equity: 12.56%
• Return on Assets: 4.11%

Debt

• Debt-to-Equity Ratio: 0.96
• Current Ratio: 3.59
• Quick Ratio: 3.59

Sales & Book Value

• Annual Sales: $7.65 million
• Price / Sales: 65.83
• Cash Flow: $0.57 per share
• Price / Cash Flow: 70.46
• Book Value: $6.77 per share
• Price / Book: 5.93

Miscellaneous

• Outstanding Shares: 12,541,000
• Free Float: 11,425,000
• Market Cap: $503.77 million
• Optionable: Optionable
• Beta: 0.86